In summary, the results emphasize the significance of ANXA1 as a relevant biomarker and therapeutic objective, and further research is warranted to elucidate its mechanisms with the ultimate goal of developing anti-ANXA1 strategies to mitigate therapeutic resistance in CRC and RC. This evidence concerns the gene ANXA1 and colorectal carcinoma.